Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer

cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

Contact: Ina Cu

              Investor Relations

              650-266-3200


CONTACT: Ina Cu, Investor Relations of Cell Genesys, Inc.,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:8/3/2015)... Ill. , Aug. 3, 2015 Your ... problem, and you,re looking for the best possible outcome. ... the best outcome too, and now there,s a ... Following steps recommended by the American Orthopaedic Foot ... surgery can help you avoid complications and heal as ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2
... 22 Dynavax,Technologies Corporation (Nasdaq: DVAX ) today ... ragweed allergy therapy, to subjects as,part of an environmental ... of 300 subjects. Subjects are being screened based on ... Exposure to ragweed allergen in,the chamber is being used ...
... 22 Boston,Scientific Corporation (NYSE: BSX ) ... which continue to support the proven safety and,efficacy ... and add to the growing body of strong ... Coronary,Stent System. An analysis of the data was ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 2Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 4
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... ... , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative ... Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in ... presentation may be accessed via the investor relations section of the Company’s website. , ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
(Date:8/3/2015)... ... , ... From 2006-2017 the number of dental laboratories in ... compiled for the National Association of Dental Laboratories ( NADL ) by Valmont ... Statistics. As the number of dental laboratories decreases, dentists will have fewer options ...
(Date:8/3/2015)... ... 03, 2015 , ... Hub International Insurance Services ... joined its growing California employee benefits division. Mr. Williams will be responsible ... Mr. Williams will be joining the newly integrated Northern California employee benefits team ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... new method for creating nanofibers made of proteins, developed ... (NYU-Poly), promises to greatly improve drug delivery methods for ... as well as aid in the regeneration of human ... this same development could point the way to even ...
... Center for Healthy Neighborhoods of Case Western Reserve ... groups on three of the most pressing public ... The three data briefs statistical public health ... prevalence estimates for diabetes, hypertension awareness and obesity ...
... -- Even when fast-food restaurants list calorie counts for menu ... information to make healthy meal choices, researchers report. In ... 200 food items on menu boards from 12 restaurant chains ... often, calorie counts were listed for combo meals or meals ...
... at Moffitt Cancer Center in Tampa, Fla., and colleagues ... prevent resistance to the chemotherapy drug vemurafenib, commonly used ... characterized by a diminished apoptosis (programmed cancer cell death) ... and cell survival is regulated by a family of ...
... National Jewish Health has received a grant for $950,308 ... Colorado,s San Luis Valley with educational materials for patients ... is the most common chronic illness in children and ... days. The San Luis Valley has one of the ...
... of all deaths in the United States are linked to ... inactivity. Despite these causal links, of the $2 trillion spent ... of that is devoted to addressing behavioral and social risk ... in behavioral and social sciences with a new $500,000 grant ...
Cached Medicine News:Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:First breakdown of public health data for Cleveland neighborhoods 2Health News:First breakdown of public health data for Cleveland neighborhoods 3Health News:Many Gaps in Fast-Food Nutrition Information 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
... Gentian violet ink ... prepping, Millimeter scale ruler ... barrel for quick measuring. ... with both inch and ...
Double-ended, one end sharp, other end blunt, 7 1/2", double-ended, 5 mm wide....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: